Cargando…

Low Resistance to First and Second Line Anti-Tuberculosis Drugs among Treatment Naive Pulmonary Tuberculosis Patients in Southwestern Uganda

BACKGROUND: There are limited data on region-specific drug susceptibility of tuberculosis (TB) in Uganda. We performed resistance testing on specimens collected from treatment-naive patients with pulmonary TB in Southwestern Uganda for first and second line anti-TB drugs. We sought to provide data t...

Descripción completa

Detalles Bibliográficos
Autores principales: Orikiriza, Patrick, Tibenderana, Becky, Siedner, Mark J., Mueller, Yolanda, Byarugaba, Frederick, Moore, Christopher C., Evans, Emily E., Bonnet, Maryline, Page, Anne-Laure, Bazira, Joel, Boum II, Yap
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320102/
https://www.ncbi.nlm.nih.gov/pubmed/25658921
http://dx.doi.org/10.1371/journal.pone.0118191
_version_ 1782356061912563712
author Orikiriza, Patrick
Tibenderana, Becky
Siedner, Mark J.
Mueller, Yolanda
Byarugaba, Frederick
Moore, Christopher C.
Evans, Emily E.
Bonnet, Maryline
Page, Anne-Laure
Bazira, Joel
Boum II, Yap
author_facet Orikiriza, Patrick
Tibenderana, Becky
Siedner, Mark J.
Mueller, Yolanda
Byarugaba, Frederick
Moore, Christopher C.
Evans, Emily E.
Bonnet, Maryline
Page, Anne-Laure
Bazira, Joel
Boum II, Yap
author_sort Orikiriza, Patrick
collection PubMed
description BACKGROUND: There are limited data on region-specific drug susceptibility of tuberculosis (TB) in Uganda. We performed resistance testing on specimens collected from treatment-naive patients with pulmonary TB in Southwestern Uganda for first and second line anti-TB drugs. We sought to provide data to guide regional recommendations for empiric TB therapy. METHODS: Archived isolates, obtained from patients at Mbarara Regional Referral Hospital from February 2009 to February 2013, were tested for resistance to isoniazid and rifampicin using the MTBDRplus and Xpert MTB/RIF assays. A subset of randomly selected isolates was tested for second line agents, including fluoroquinolones (FQs), aminoglycosides, cyclic peptides, and ethambutol using the MTBDRsl assay. We performed confirmatory testing for FQ resistance using repeated MTBDRsl, the Mycobacteria growth indicator tube (MGIT) assay, and sequencing of the gyrA and gyrB genes. RESULTS: We tested isolates from 190 patients. The cohort had a median age of 33 years (IQR 26-43), 69% (131/190) were male, and the HIV prevalence was 42% (80/190). No isolates (0/190) were rifampicin-resistant and only 1/190 (0.5%) was isoniazid-resistant. Among 92 isolates tested for second-line drug resistance, 71 (77%) had interpretable results, of which none were resistant to aminoglycosides, cyclic peptides or ethambutol. Although 7 (10%) initially tested as resistant to FQs by the MTBDRsl assay, they were confirmed as susceptible by repeat MTBDRsl testing as well as by MGIT and gyrase gene sequencing CONCLUSION: We found no MDR-TB and no resistance to ethambutol, FQs, or injectable anti-TB drugs in treatment naïve patients with pulmonary TB in Southwestern Uganda. Standard treatment guidelines for susceptible TB should be adequate for most patients with TB in this population. Where possible, molecular susceptibility testing methods should be routinely validated by culture methods.
format Online
Article
Text
id pubmed-4320102
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-43201022015-02-18 Low Resistance to First and Second Line Anti-Tuberculosis Drugs among Treatment Naive Pulmonary Tuberculosis Patients in Southwestern Uganda Orikiriza, Patrick Tibenderana, Becky Siedner, Mark J. Mueller, Yolanda Byarugaba, Frederick Moore, Christopher C. Evans, Emily E. Bonnet, Maryline Page, Anne-Laure Bazira, Joel Boum II, Yap PLoS One Research Article BACKGROUND: There are limited data on region-specific drug susceptibility of tuberculosis (TB) in Uganda. We performed resistance testing on specimens collected from treatment-naive patients with pulmonary TB in Southwestern Uganda for first and second line anti-TB drugs. We sought to provide data to guide regional recommendations for empiric TB therapy. METHODS: Archived isolates, obtained from patients at Mbarara Regional Referral Hospital from February 2009 to February 2013, were tested for resistance to isoniazid and rifampicin using the MTBDRplus and Xpert MTB/RIF assays. A subset of randomly selected isolates was tested for second line agents, including fluoroquinolones (FQs), aminoglycosides, cyclic peptides, and ethambutol using the MTBDRsl assay. We performed confirmatory testing for FQ resistance using repeated MTBDRsl, the Mycobacteria growth indicator tube (MGIT) assay, and sequencing of the gyrA and gyrB genes. RESULTS: We tested isolates from 190 patients. The cohort had a median age of 33 years (IQR 26-43), 69% (131/190) were male, and the HIV prevalence was 42% (80/190). No isolates (0/190) were rifampicin-resistant and only 1/190 (0.5%) was isoniazid-resistant. Among 92 isolates tested for second-line drug resistance, 71 (77%) had interpretable results, of which none were resistant to aminoglycosides, cyclic peptides or ethambutol. Although 7 (10%) initially tested as resistant to FQs by the MTBDRsl assay, they were confirmed as susceptible by repeat MTBDRsl testing as well as by MGIT and gyrase gene sequencing CONCLUSION: We found no MDR-TB and no resistance to ethambutol, FQs, or injectable anti-TB drugs in treatment naïve patients with pulmonary TB in Southwestern Uganda. Standard treatment guidelines for susceptible TB should be adequate for most patients with TB in this population. Where possible, molecular susceptibility testing methods should be routinely validated by culture methods. Public Library of Science 2015-02-06 /pmc/articles/PMC4320102/ /pubmed/25658921 http://dx.doi.org/10.1371/journal.pone.0118191 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
spellingShingle Research Article
Orikiriza, Patrick
Tibenderana, Becky
Siedner, Mark J.
Mueller, Yolanda
Byarugaba, Frederick
Moore, Christopher C.
Evans, Emily E.
Bonnet, Maryline
Page, Anne-Laure
Bazira, Joel
Boum II, Yap
Low Resistance to First and Second Line Anti-Tuberculosis Drugs among Treatment Naive Pulmonary Tuberculosis Patients in Southwestern Uganda
title Low Resistance to First and Second Line Anti-Tuberculosis Drugs among Treatment Naive Pulmonary Tuberculosis Patients in Southwestern Uganda
title_full Low Resistance to First and Second Line Anti-Tuberculosis Drugs among Treatment Naive Pulmonary Tuberculosis Patients in Southwestern Uganda
title_fullStr Low Resistance to First and Second Line Anti-Tuberculosis Drugs among Treatment Naive Pulmonary Tuberculosis Patients in Southwestern Uganda
title_full_unstemmed Low Resistance to First and Second Line Anti-Tuberculosis Drugs among Treatment Naive Pulmonary Tuberculosis Patients in Southwestern Uganda
title_short Low Resistance to First and Second Line Anti-Tuberculosis Drugs among Treatment Naive Pulmonary Tuberculosis Patients in Southwestern Uganda
title_sort low resistance to first and second line anti-tuberculosis drugs among treatment naive pulmonary tuberculosis patients in southwestern uganda
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320102/
https://www.ncbi.nlm.nih.gov/pubmed/25658921
http://dx.doi.org/10.1371/journal.pone.0118191
work_keys_str_mv AT orikirizapatrick lowresistancetofirstandsecondlineantituberculosisdrugsamongtreatmentnaivepulmonarytuberculosispatientsinsouthwesternuganda
AT tibenderanabecky lowresistancetofirstandsecondlineantituberculosisdrugsamongtreatmentnaivepulmonarytuberculosispatientsinsouthwesternuganda
AT siednermarkj lowresistancetofirstandsecondlineantituberculosisdrugsamongtreatmentnaivepulmonarytuberculosispatientsinsouthwesternuganda
AT muelleryolanda lowresistancetofirstandsecondlineantituberculosisdrugsamongtreatmentnaivepulmonarytuberculosispatientsinsouthwesternuganda
AT byarugabafrederick lowresistancetofirstandsecondlineantituberculosisdrugsamongtreatmentnaivepulmonarytuberculosispatientsinsouthwesternuganda
AT moorechristopherc lowresistancetofirstandsecondlineantituberculosisdrugsamongtreatmentnaivepulmonarytuberculosispatientsinsouthwesternuganda
AT evansemilye lowresistancetofirstandsecondlineantituberculosisdrugsamongtreatmentnaivepulmonarytuberculosispatientsinsouthwesternuganda
AT bonnetmaryline lowresistancetofirstandsecondlineantituberculosisdrugsamongtreatmentnaivepulmonarytuberculosispatientsinsouthwesternuganda
AT pageannelaure lowresistancetofirstandsecondlineantituberculosisdrugsamongtreatmentnaivepulmonarytuberculosispatientsinsouthwesternuganda
AT bazirajoel lowresistancetofirstandsecondlineantituberculosisdrugsamongtreatmentnaivepulmonarytuberculosispatientsinsouthwesternuganda
AT boumiiyap lowresistancetofirstandsecondlineantituberculosisdrugsamongtreatmentnaivepulmonarytuberculosispatientsinsouthwesternuganda